PQA-18 (0.5 mg/kg, i.p., three times a week) displays immunosuppressing activity in C57BL/6J mice immunized with NP-CGG, with inhibiting the population of a subset of regulatory T cells and the immunoglobulin (Ig) production against T cell-dependent antigens[1].
PQA-18 ointment (100 mg/mouse, contains 0.05%-0.1% PQA-18, three times a week, 17 weeks) improves dermatitis and IgE levels in Nc/Nga mice[1].
| Animal Model: | Male C57BL/6J mice (10 weeks old) immunized by intraperitoneal injection of 50 μg NP-CGG[1] |
| Dosage: | 0.5 mg/kg |
| Administration: | Intraperitoneal injection (i.p.); three times a week |
| Result: | Suppressed the NP-specific responses (IgM, IgG1, and IgG3) in peripheral blood.
Significantly suppressed the number of Foxp3+CD4+CD25+ cells in spleens.
|
